Clinical and cortical decline in the aphasic variant of Alzheimer's disease

Emily Joy Rogalski; Jaiashre Sridhar; Adam Martersteck; Benjamin Rader; Derin Cobia; Anupa K. Arora; Angela J. Fought; Eileen H. Bigio; Sandra Weintraub; Marek Marsel Mesulam; Alfred Rademaker

doi:10.1016/j.jalz.2018.12.003

Clinical and cortical decline in the aphasic variant of Alzheimer's disease

Emily Joy Rogalski^*, Jaiashre Sridhar, Adam Martersteck, Benjamin Rader, Derin Cobia, Anupa K. Arora, Angela J. Fought, Eileen H. Bigio, Sandra Weintraub, Marek Marsel Mesulam, Alfred Rademaker

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Introduction: Primary progressive aphasia (PPA) displays variable progression trajectories that require further elucidation. Methods: Longitudinal quantitation of atrophy and language over 12 months was completed for PPA patients with and without positive amyloid PET (PPA ^Aβ+ and PPA ^Aβ− ), an imaging biomarker of underlying Alzheimer's disease. Results: Over 12 months, both PPA groups showed significantly greater cortical atrophy rates in the left versus right hemisphere, with a more widespread pattern in PPA ^Aβ+ . The PPA ^Aβ+ group also showed greater decline in performance on most language tasks. There was no obligatory relationship between the logopenic PPA variant and amyloid status. Effect sizes from quantitative MRI data were more robust than neuropsychological metrics. Discussion: Preferential language network neurodegeneration is present in PPA irrespective of amyloid status. Clinical and anatomical progression appears to differ for PPA due to Alzheimer's disease versus non–Alzheimer's disease neuropathology, a distinction that may help to inform prognosis and the design of intervention trials.

Original language	English (US)
Pages (from-to)	543-552
Number of pages	10
Journal	Alzheimer's and Dementia
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.jalz.2018.12.003
State	Published - Apr 2019

Keywords

Amyloid PET
Biomarker
FreeSurfer
Frontotemporal dementia
Frontotemporal lobar degeneration
Neuropsychology
Primary progressive aphasia
Progression
Volumetric MRI

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.jalz.2018.12.003

Fingerprint Dive into the research topics of 'Clinical and cortical decline in the aphasic variant of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this

@article{d97720defec940ebaf957e43f18974ba,

title = "Clinical and cortical decline in the aphasic variant of Alzheimer's disease",

abstract = " Introduction: Primary progressive aphasia (PPA) displays variable progression trajectories that require further elucidation. Methods: Longitudinal quantitation of atrophy and language over 12 months was completed for PPA patients with and without positive amyloid PET (PPA Aβ+ and PPA Aβ− ), an imaging biomarker of underlying Alzheimer's disease. Results: Over 12 months, both PPA groups showed significantly greater cortical atrophy rates in the left versus right hemisphere, with a more widespread pattern in PPA Aβ+ . The PPA Aβ+ group also showed greater decline in performance on most language tasks. There was no obligatory relationship between the logopenic PPA variant and amyloid status. Effect sizes from quantitative MRI data were more robust than neuropsychological metrics. Discussion: Preferential language network neurodegeneration is present in PPA irrespective of amyloid status. Clinical and anatomical progression appears to differ for PPA due to Alzheimer's disease versus non–Alzheimer's disease neuropathology, a distinction that may help to inform prognosis and the design of intervention trials. ",

keywords = "Amyloid PET, Biomarker, FreeSurfer, Frontotemporal dementia, Frontotemporal lobar degeneration, Neuropsychology, Primary progressive aphasia, Progression, Volumetric MRI",

author = "Rogalski, {Emily Joy} and Jaiashre Sridhar and Adam Martersteck and Benjamin Rader and Derin Cobia and Arora, {Anupa K.} and Fought, {Angela J.} and Bigio, {Eileen H.} and Sandra Weintraub and Mesulam, {Marek Marsel} and Alfred Rademaker",

note = "Funding Information: Study Funding: This project was supported in part by DC008552 from the National Institute on Deafness and Communication Disorders ; AG13854 (Alzheimer Disease Core Center) and AG056258 from the National Institute on Aging ; and NS075075 from the National Institute of Neurological Disorders and Stroke (NINDS). ",

year = "2019",

month = apr,

doi = "10.1016/j.jalz.2018.12.003",

language = "English (US)",

volume = "15",

pages = "543--552",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "4",

}

Clinical and cortical decline in the aphasic variant of Alzheimer's disease. / Rogalski, Emily Joy; Sridhar, Jaiashre; Martersteck, Adam; Rader, Benjamin; Cobia, Derin; Arora, Anupa K.; Fought, Angela J.; Bigio, Eileen H.; Weintraub, Sandra ; Mesulam, Marek Marsel ; Rademaker, Alfred.

In: Alzheimer's and Dementia, Vol. 15, No. 4, 04.2019, p. 543-552.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Clinical and cortical decline in the aphasic variant of Alzheimer's disease

AU - Rogalski, Emily Joy

AU - Sridhar, Jaiashre

AU - Martersteck, Adam

AU - Rader, Benjamin

AU - Cobia, Derin

AU - Arora, Anupa K.

AU - Fought, Angela J.

AU - Bigio, Eileen H.

AU - Weintraub, Sandra

AU - Mesulam, Marek Marsel

AU - Rademaker, Alfred

N1 - Funding Information: Study Funding: This project was supported in part by DC008552 from the National Institute on Deafness and Communication Disorders ; AG13854 (Alzheimer Disease Core Center) and AG056258 from the National Institute on Aging ; and NS075075 from the National Institute of Neurological Disorders and Stroke (NINDS).

PY - 2019/4

Y1 - 2019/4

N2 - Introduction: Primary progressive aphasia (PPA) displays variable progression trajectories that require further elucidation. Methods: Longitudinal quantitation of atrophy and language over 12 months was completed for PPA patients with and without positive amyloid PET (PPA Aβ+ and PPA Aβ− ), an imaging biomarker of underlying Alzheimer's disease. Results: Over 12 months, both PPA groups showed significantly greater cortical atrophy rates in the left versus right hemisphere, with a more widespread pattern in PPA Aβ+ . The PPA Aβ+ group also showed greater decline in performance on most language tasks. There was no obligatory relationship between the logopenic PPA variant and amyloid status. Effect sizes from quantitative MRI data were more robust than neuropsychological metrics. Discussion: Preferential language network neurodegeneration is present in PPA irrespective of amyloid status. Clinical and anatomical progression appears to differ for PPA due to Alzheimer's disease versus non–Alzheimer's disease neuropathology, a distinction that may help to inform prognosis and the design of intervention trials.

AB - Introduction: Primary progressive aphasia (PPA) displays variable progression trajectories that require further elucidation. Methods: Longitudinal quantitation of atrophy and language over 12 months was completed for PPA patients with and without positive amyloid PET (PPA Aβ+ and PPA Aβ− ), an imaging biomarker of underlying Alzheimer's disease. Results: Over 12 months, both PPA groups showed significantly greater cortical atrophy rates in the left versus right hemisphere, with a more widespread pattern in PPA Aβ+ . The PPA Aβ+ group also showed greater decline in performance on most language tasks. There was no obligatory relationship between the logopenic PPA variant and amyloid status. Effect sizes from quantitative MRI data were more robust than neuropsychological metrics. Discussion: Preferential language network neurodegeneration is present in PPA irrespective of amyloid status. Clinical and anatomical progression appears to differ for PPA due to Alzheimer's disease versus non–Alzheimer's disease neuropathology, a distinction that may help to inform prognosis and the design of intervention trials.

KW - Amyloid PET

KW - Biomarker

KW - FreeSurfer

KW - Frontotemporal dementia

KW - Frontotemporal lobar degeneration

KW - Neuropsychology

KW - Primary progressive aphasia

KW - Progression

KW - Volumetric MRI

UR - http://www.scopus.com/inward/record.url?scp=85061268956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061268956&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2018.12.003

DO - 10.1016/j.jalz.2018.12.003

M3 - Article

C2 - 30765195

AN - SCOPUS:85061268956

VL - 15

SP - 543

EP - 552

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 4

ER -